PDF
File
Kurs
-1,91%
Likviditet
0,11 MSEK
Kalender
| Est. tid* | ||
| 2025-11-25 | 05:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-26 | 05:00 | Kvartalsrapport 2025-Q2 |
| 2025-06-23 | - | Årsstämma |
| 2025-05-23 | - | Kvartalsrapport 2025-Q1 |
| 2025-05-02 | - | X-dag ordinarie utdelning DBP B 0.00 SEK |
| 2025-02-27 | - | Bokslutskommuniké 2024 |
| 2024-11-14 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-26 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-13 | - | Kvartalsrapport 2024-Q1 |
| 2024-04-26 | - | X-dag ordinarie utdelning DBP B 0.00 SEK |
| 2024-04-25 | - | Årsstämma |
| 2024-02-27 | - | Bokslutskommuniké 2023 |
| 2023-11-14 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-25 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-25 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-19 | - | X-dag ordinarie utdelning DBP B 0.00 SEK |
| 2023-05-17 | - | Årsstämma |
| 2023-02-24 | - | Bokslutskommuniké 2022 |
| 2022-11-14 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-27 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-27 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-11 | - | Extra Bolagsstämma 2022 |
| 2022-04-08 | - | X-dag ordinarie utdelning DBP B 0.00 SEK |
| 2022-04-07 | - | Årsstämma |
| 2022-02-25 | - | Bokslutskommuniké 2021 |
| 2021-11-12 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-27 | - | Kvartalsrapport 2021-Q2 |
| 2021-04-21 | - | Årsstämma |
| 2021-04-21 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-08 | - | X-dag ordinarie utdelning DBP B 0.00 SEK |
| 2021-02-25 | - | Bokslutskommuniké 2020 |
| 2020-11-23 | - | Kvartalsrapport 2020-Q3 |
| 2020-09-07 | - | Extra Bolagsstämma 2020 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-12 | - | X-dag ordinarie utdelning DBP B 0.00 SEK |
| 2020-06-11 | - | Årsstämma |
| 2020-05-07 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-21 | - | Bokslutskommuniké 2019 |
| 2019-11-25 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-27 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-07 | - | Kvartalsrapport 2019-Q1 |
| 2019-04-09 | - | X-dag ordinarie utdelning DBP B 0.00 SEK |
| 2019-04-08 | - | Årsstämma |
| 2018-11-13 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-27 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-07 | - | Kvartalsrapport 2018-Q1 |
| 2018-04-10 | - | X-dag ordinarie utdelning DBP B 0.00 SEK |
| 2018-04-09 | - | Årsstämma |
| 2018-02-23 | - | Bokslutskommuniké 2017 |
| 2017-08-25 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-09 | - | X-dag ordinarie utdelning DBP B 0.00 SEK |
| 2017-05-08 | - | Årsstämma |
| 2017-05-05 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-20 | - | Bokslutskommuniké 2016 |
| 2016-11-11 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-26 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-10 | - | X-dag ordinarie utdelning DBP B 0.00 SEK |
| 2016-05-09 | - | Årsstämma |
| 2016-05-04 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-19 | - | Bokslutskommuniké 2015 |
| 2015-10-23 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-14 | - | Kvartalsrapport 2015-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Double Bond Pharmaceutical International AB (publ) ("DBP") is delighted to announce that the long term GLP toxicity study of SI-053 in rats has been successfully completed.
The purpose of this study was to evaluate the potential toxicity of intracerebral administration of SI-053 in combination with subsequent adapted chemo-radiation treatment (Standard of Care for Glioblastoma).
The in vivo model consisted of application of SI-053 at low, middle, and high doses which were followed by one cycle of oral Temozolomide and irradiation in rats.
The study also revealed that the excipient showed no toxicity. Additionally, the study results support the safety of the starting dose in the planned clinical trial.
`'The study was elegantly designed according to EMA's scientific advice, which provided a proper marginal of safety for the starting dose in humans. Together with efficacy and PK studies, the whole preclinical data package strengthens the scientific rationale for the clinical trial of SI-053 and supports DBP's goal to improve the treatment of Glioblastoma,'' - comments Dr. Lili Li, Vice Director of Preclinical Development and Senior Medical Director of Clinical Development.
"Our team has done a great job by managing the preclinical development for SI-053," - comments Igor Lokot, CEO of DBP, - "Success leads to success: we are very enthusiastic about the next phase of the SI-053 development - planned clinical trials."
10 communicated
milestones
between Q3 2020
to Q2
2021https://mb.c
ision.com/Main/1
2720/3191146/130
4323.pdf
Milestone Comments Status
Preclinical: Finalized Done
Efficacy of SI
-053 in
subcutaneous
tumor in mice
Preclinical: Finalized Done
Biodistribution
of SI053 after
intracerebral
administration
in rats
Preclinical: Finalized Done
Toxicity
studies of SI
-053 after
intracerebral
administration
in rats
Clinical: Key Finalized Done
Opinion Leader
(KOL) meeting,
an important
milestone for
SI-053 Phase 1
clinical study
Clinical: Q2 2021
Feasibility
studies for
clinical site
selection for
Phase 1 SI-053
clinical study
CMC: Finalized Done
Sterilization
of SI-053 will
be validated
CMC: Stability Finalized Done
study for SI
-053 has been
started
CMC: The IMPD Q1 2021
is completed
Regulatory: Q2 2021
Clinical trial
application
(CTA) for Phase
1 SI-053
clinical study
Financing phase Q2 2021 - issuance of units as a probable alternative
1